Propafenone Hydrochloride Extended-Release Capsules Recalled for CGMP Deviations
Glenmark Pharmaceuticals Inc. is recalling Propafenone Hydrochloride Extended-Release Capsules 325mg (Lot #17230767, expiring Mar-25) distributed nationwide due to current Good Manufacturing Practice (CGMP) deviations. Patients taking this medication should consult their physician before discontinuing use.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall involving CGMP deviations in a prescription drug. The source text contains no reports of illness, injury, or adverse health consequences. Per the rubric, CGMP deviations without reported harm and with no high-risk pathogen or serious safety defect constitute a Moderate recall.
Plain-English summary
Glenmark Pharmaceuticals Inc., USA is voluntarily recalling Propafenone Hydrochloride Extended-Release Capsules 325mg, 60-count bottles (NDC# 68462-409-60) distributed nationwide. The recall affects Lot #17230767 with an expiration date of March 2025.
The recall was initiated due to current Good Manufacturing Practice (CGMP) deviations identified during manufacturing. The firm notified the FDA by letter on March 13, 2025, and the FDA classified this as a Class II recall on April 8, 2025.
Propafenone is a prescription antiarrhythmic medication used to treat abnormal heart rhythms. Patients currently taking this medication should not stop taking it without consulting their physician, as doing so could have serious health consequences. Affected patients should contact their pharmacy or healthcare provider for guidance on next steps or alternative sources of the medication.
Anyone with questions about this recall or who believes they have received affected product should contact Glenmark Pharmaceuticals Inc. USA at the address listed on the bottle or through the FDA's online resources.
The recalled product
- Product
- PROPAFENONE HYDROCHLORIDE (PROPAFENONE HYDROCHLORIDE)
- Brand
- PROPAFENONE HYDROCHLORIDE
- Manufacturer
- Glenmark Pharmaceuticals Inc., USA
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot # 17230767
- exp. date Mar-25
UPCs (3)
- 0368462409602
- 0368462410608
- 0368462408605
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 39 recalled by Glenmark Pharmaceuticals Inc., USA under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 39 products in this recall →Related recalls
Same brand · PROPAFENONE HYDROCHLORIDE
- ModeratePropafenone Hydrochloride Extended-Release Capsules Recalled for CGMP Deviations
FDA (Drugs) · 2025-04-16
- ModeratePropafenone Hydrochloride Extended-Release Capsules Recalled for CGMP Deviations
FDA (Drugs) · 2025-04-16
- ModeratePropafenone Hydrochloride Extended-Release Capsules Recalled for CGMP Deviations
FDA (Drugs) · 2025-04-16
Same manufacturer · Glenmark Pharmaceuticals Inc., USA
See all →- ModerateAzelaic Acid Gel 15% Recalled Over Grainy, Gritty, or Sandy Texture
FDA (Drugs) · 2026-08-05
- ModerateAlyacen 7/7/7 birth control tablets failed total impurities specification
FDA (Drugs) · 2026-06-24
- ModerateOndansetron tablets recalled because blister packs are not fully sealed
FDA (Drugs) · 2026-01-07
- CriticalFrozen chopped methi recalled after testing positive for Salmonella
FDA (Drugs) · 2025-12-17
- ModerateBisoprolol and hydrochlorothiazide tablets recalled over traces of another drug
FDA (Drugs) · 2025-12-10
Same hazard · cgmp deviation
See all →- SevereZicam Cold Remedy Nasal Swabs Recalled for Microbiological Testing Failures
FDA (Drugs) · 2026-09-02
- ModerateGolden State Medical Supply Recalls Carbamazepine Tablets Due to CGMP Deviations
FDA (Drugs) · 2026-08-26
- HighShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- ModerateSildenafil Citrate USP Recalled for CGMP Deviations Noted During FDA Inspection
FDA (Drugs) · 2026-08-19
- ModerateSildenafil Citrate Recall Due to CGMP Deviations
FDA (Drugs) · 2026-08-19